Get the Stockscreener App
463.13
6.92%
29.98
After Hours:
462.45
-0.68
-0.15%
Vertex Pharmaceuticals Inc stock is traded at $463.13, with a volume of 2.52M.
It is up +6.92% in the last 24 hours and up +8.72% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$433.15
Open:
$440.31
24h Volume:
2.52M
Relative Volume:
1.69
Market Cap:
$117.50B
Revenue:
$11.74B
Net Income/Loss:
$3.68B
P/E Ratio:
32.64
EPS:
14.1888
Net Cash Flow:
$3.34B
1W Performance:
+7.16%
1M Performance:
+8.72%
6M Performance:
+3.73%
1Y Performance:
+1.35%
1-Day Range:
$439.35
$463.85
1-Week Range:
$423.45
$463.85
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
463.13 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.67 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
473.29 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.80 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.78 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Check Out What Whales Are Doing With VRTX - Benzinga
Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Op - GuruFocus
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Finviz
Vertex upgraded at Morgan Stanley on kidney pipeline - Seeking Alpha
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Vertex Wins Wall Street Back With Kidney Drug Bets - Finimize
Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Receives Rating Upgrade from Morgan Stanley | VRTX Stock News - GuruFocus
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Transcript : Vertex Pharmaceuticals Incorporated Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 09 - MarketScreener
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessQuarterly Market Summary & Stepwise Swing Trade Plans - Newser
Is Vertex Pharmaceuticals Incorporated stock resilient to inflationJuly 2025 Fed Impact & Consistent Profit Alerts - Newser
Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight From Equalweight, Adjusts PT to $516 From $438 - MarketScreener
Morgan Stanley upgrades Vertex stock to Overweight on kidney pipeline potential - Investing.com India
Published on: 2025-12-02 23:32:41 - Newser
Akeso’s Goals Beyond Ivonescimab: ‘We Can Hit Vertex And Regeneron-Level Innovation’ - Citeline News & Insights
Why Vertex Pharmaceuticals Incorporated stock appeals to dividend seekersJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - Newser
Can Vertex Pharmaceuticals Incorporated (VX1) stock sustain breakout momentum2025 Technical Overview & High Accuracy Swing Entry Alerts - Newser
Why Vertex Pharmaceuticals Incorporated (VX1) stock stays resilientTrade Analysis Summary & Daily Oversold Stock Bounce Ideas - Newser
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - sharewise.com
Is Vertex Pharmaceuticals Incorporated stock ready for breakoutEarnings Growth Report & Low Risk High Reward Ideas - moha.gov.vn
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? - MSN
Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - Yahoo Finance
How analysts rate Vertex Pharmaceuticals Incorporated stock today2025 Key Highlights & Scalable Portfolio Growth Methods - BỘ NỘI VỤ
Is Vertex Still a Bargain After Latest Pipeline Progress and Five Year 90.6% Gain? - Yahoo Finance
Where Will Vertex Pharmaceuticals Be in 5 Years - sharewise.com
Vertex Pharmaceuticals names Wafi Alshehri as HRBP Director for KSA and the GCC - Indiatimes
What Do Analysts Think About Vertex Pharmaceuticals (VRTX)? - Finviz
Interest rate-sensitive biotech companies are bullish on the New York Stock Exchange. Hedge funds ha.. - 매일경제
Scotiabank Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Leads Hedge Fund Interest in Q3 20 - GuruFocus
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon - Finviz
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why - Finviz
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Is Vertex Pharmaceuticals Incorporated a good long term investmentVolatility Index Analysis & Big Returns Low Cost - earlytimes.in
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings - MSN
[Form 4] VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity - Stock Titan
Shareholder Carney Lloyd Foundation Files To Sell 800 Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
2 Inflation-Proof Growth Stocks That Could Outperform the Market - Finviz
Vertex Nears Historic Breakthrough: Stem Cell Therapy Poised to Transform Type 1 Diabetes Treatment - Azat TV
Vertex Pharmaceuticals Incorporated (0QZU.IL) stock price, news, quote and history - Yahoo Finance UK
How risky is Vertex Pharmaceuticals Incorporated (VX1) stock compared to peers2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataGold Moves & Weekly Chart Analysis and Guides - newser.com
Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - Bloomberg Law News
Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Vertex Pharmaceuticals Inc. Stock Falls 3.3%, Underperforms Peers - 富途牛牛
VP Atkinson III Sells 2,500 ($1.1M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):